Dana-Farber Cancer Institute: all 833 studies

Page 3 of 9. Open to participants first (121), then studies with results posted, then the rest; newest registration first within each.

• Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility StudyCompletedNCT03170648Not applicableResults posted
• Palbociclib After CDK and Endocrine Therapy (PACE)Active, not recruitingNCT03147287Phase 2Results posted
• Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.TerminatedNCT03137537Phase 2Results posted
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid CancerTerminatedNCT03131206Phase 1/2Results posted
• Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast CancerTerminatedNCT03130439Phase 2Results posted
• LY3022855 With BRAF/MEK Inhibition in Patients With MelanomaCompletedNCT03101254Phase 1/2Results posted
• Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPCCompletedNCT03093428Phase 2Results posted
• A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate CancerTerminatedNCT03093272Phase 2Results posted
• Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaCompletedNCT03087019Phase 2Results posted
• Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHNActive, not recruitingNCT03085719Phase 2Results posted
• A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural MesotheliomaTerminatedNCT03075527Phase 2Results posted
• PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical LesionsActive, not recruitingNCT03070236Not applicableResults posted
• A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's SyndromeActive, not recruitingNCT03054896Phase 2Results posted
• Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BCTerminatedNCT03051672Phase 2Results posted
• A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast CancerCompletedNCT03051659Phase 2Results posted
• A Study Of Pembrolizumab In Combination With Trastuzumab-DM1CompletedNCT03032107Phase 1Results posted
• The HOPE Trial and the SMART StudyCompletedNCT03022032Not applicableResults posted
• CISPLATIN + AZD-1775 In Breast CancerCompletedNCT03012477Phase 2Results posted
• A Study of Abemaciclib in Recurrent GlioblastomaActive, not recruitingNCT02981940Phase 2Results posted
• Reduction of Post Mastectomy Pain With the Jacki® Recovery JacketCompletedNCT02976103Not applicableResults posted
• Pembrolizumab in Refractory Advanced Esophageal CancerCompletedNCT02971956Phase 2Results posted
• Improving Communication Between Cancer Patients & OncologistsCompletedNCT02969031Not applicableResults posted
• Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant TherapyCompletedNCT02956473Not applicableResults posted
• Merestinib In Non-Small Cell Lung Cancer And Solid TumorsTerminatedNCT02920996Phase 2Results posted
• Pembrolizumab in Metastatic Anal CancerCompletedNCT02919969Phase 2Results posted
• Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityActive, not recruitingNCT02919683Phase 2Results posted
• A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin LymphomaCompletedNCT02919670Not applicableResults posted
• Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple MyelomaCompletedNCT02916771Phase 2Results posted
• Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerActive, not recruitingNCT02912572Phase 2Results posted
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaCompletedNCT02903381Phase 2Results posted
• Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing ProstatectomyCompletedNCT02903368Phase 2Results posted
• Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the BoneActive, not recruitingNCT02880319Phase 2Results posted
• Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerCompletedNCT02876302Phase 2Results posted
• A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair DeficiencyCompletedNCT02873975Phase 2Results posted
• A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibActive, not recruitingNCT02873962Phase 2Results posted
• Palbociclib With Everolimus + Exemestane In BCCompletedNCT02871791Phase 1/2Results posted
• Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell TransplantationCompletedNCT02867384Phase 2Results posted
• Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal CancerCompletedNCT02865811Phase 2Results posted
• Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal CancerCompletedNCT02865135Phase 1/2Results posted
• A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive GlioblastomaActive, not recruitingNCT02852655Phase 1Results posted
• A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid TumorsCompletedNCT02795858Phase 2Results posted
• Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung CancerTerminatedNCT02770014Phase 2Results posted
• Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)Active, not recruitingNCT02764541Phase 2Results posted
• Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaCompletedNCT02724878Phase 2Results posted
• Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer PatientsCompletedNCT02706249Phase 2Results posted
• Avoiding Growth Factor During Paclitaxel Treatment in Breast CancerCompletedNCT02698891Phase 2Results posted
• Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström MacroglobulinemiaCompletedNCT02677324Phase 2Results posted
• Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic SyndromeActive, not recruitingNCT02670525Not applicableResults posted
• A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological CancerTerminatedNCT02661815Phase 1Results posted
• A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid CancerCompletedNCT02657551Phase 2Results posted
• An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.CompletedNCT02657343Phase 1/2Results posted
• An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaActive, not recruitingNCT02648997Phase 2Results posted
• Gut Decontamination In Pediatric Allogeneic HematopoieticCompletedNCT02641236Phase 2Results posted
• A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast CancerActive, not recruitingNCT02623972Phase 2Results posted
• Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome SequencingCompletedNCT02604511Phase 2Results posted
• Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms TumorsTerminatedNCT02581384Phase 1/2Results posted
• A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT02537613Phase 1Results posted
• Lenalidomide for Adult Histiocyte DisordersActive, not recruitingNCT02523040Phase 2Results posted
• MLN0128 in Recurrent/Metastatic Merkel Cell CarcinomaCompletedNCT02514824Phase 1/2Results posted
• A Selective Androgen Receptor Modulator for Symptom Management in Prostate CancerCompletedNCT02499497Phase 2Results posted
• Trial of Ponatinib in Patients With Bevacizumab-Refractory GlioblastomaCompletedNCT02478164Phase 2Results posted
• Incorporating MR Imaging Into Prostate Radiotherapy Treatment PlanningCompletedNCT02470910Not applicableResults posted
• A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast CancerCompletedNCT02448771Phase 1/2Results posted
• Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple MyelomaCompletedNCT02441686Phase 2Results posted
• Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström MacroglobulinemiaTerminatedNCT02439138Phase 2Results posted
• Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related DisordersActive, not recruitingNCT02425904Phase 2Results posted
• Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's MacroglobulinemiaCompletedNCT02400437Phase 2Results posted
• The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) StudyCompletedNCT02390414Results posted
• Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedNCT02375555Phase 2Results posted
• Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHLCompletedNCT02362997Phase 2Results posted
• Patient-Centered Care for the Older Adult With Hematologic MalignancyCompletedNCT02359838Not applicableResults posted
• A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHDCompletedNCT02340676Phase 2Results posted
• Pembrolizumab +/- Bevacizumab for Recurrent GBMCompletedNCT02337491Phase 2Results posted
• T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAActive, not recruitingNCT02326974Phase 2Results posted
• Improving Informed Consent for Palliative ChemotherapyCompletedNCT02282722Not applicableResults posted
• E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaCompletedNCT02279394Phase 2Results posted
• A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLCompletedNCT02268851Phase 1Results posted
• Enzalutamide/Leuprolide +/- Abiraterone/Pred in ProstateCompletedNCT02268175Phase 2Results posted
• Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain MetastasesCompletedNCT02260531Phase 2Results posted
• A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02251548Phase 2Results posted
• Impact of Radiation Therapy on Breast Conservation in DCISCompletedNCT02248662Results posted
• A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid CancerCompletedNCT02244463Phase 1/2Results posted
• Everolimus for Cancer With TSC1 or TSC2 MutationCompletedNCT02201212Phase 2Results posted
• Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHDCompletedNCT02176031Phase 2Results posted
• Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GISTCompletedNCT02164240Phase 1Results posted
• A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLActive, not recruitingNCT02158091Phase 1/2Results posted
• Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast CancerTerminatedNCT02137252Phase 2Results posted
• A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLCompletedNCT02135133Phase 2Results posted
• An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-DiseaseTerminatedNCT02123966Phase 2Results posted
• Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and NeckCompletedNCT02113878Phase 1Results posted
• A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT02086175Phase 2Results posted
• Image-guided Cryoablation of Head, Neck and Spine TumorsCompletedNCT02085941Not applicableResults posted
• Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory BrcaCompletedNCT02041429Phase 1/2Results posted
• Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerCompletedNCT02040857Phase 2Results posted
• Cabozantinib in Recurrent/Metastatic Merkel Cell CarcinomaTerminatedNCT02036476Phase 2Results posted
• Enzalutamide + External Beam Rt For ProstateCompletedNCT02028988Phase 2Results posted
• Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate CancerCompletedNCT02025010Phase 2Results posted
• PET/CT-Assessment of Liver Tumor AblationCompletedNCT02018107Not applicableResults posted
• Cisplatin vs Paclitaxel for Triple Negative Breast CancerCompletedNCT01982448Phase 2Results posted
• Tivozanib As Maintenance Therapy In GYNTerminatedNCT01972516Phase 2Results posted

← Dana-Farber Cancer Institute overview and focus areas